These results warrant the inclusion of HLA-A, -B/C and HLA-E as biomarkers to predict the response to immunotherapy and the use of HLA-E or NKG2A blocking antibodies for the treatment of NSCLC. Here, HLA-E is linked to non-small cell lung carcinoma.